The Journal of Urology Vol. 197 (2017): January

Most Comprehensive and Affordable Self-study CME Product!

Make the most of your Journal of Urology® Subscription

Developed by a team of educators, academicians, and clinicians, this valuable home study activity will enhance your knowledge of urology and improve performance as well as patient care at your convenience. For just $2.50 per credit, the Home Study program is designed to provide urologists and residents affordable access to the most recent developments and techniques in urology while reading The Journal®.

Each month includes 5 clinically-relevant, selected articles with a corresponding online test for each of the 12 issues of The Journal®.

The American Urological Association designates this enduring material for a maximum of 24 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This Home Study Course is available only to subscribers of The Journal of Urology® and includes volumes 197 and 198.

 

Target Audience

This course is designed for:

  • Practicing Urologists
  • American Board of Urology (ABU) candidates
  • Residents

Learning Objectives

After completing each lesson, the participants should be able to:

  1. Assess their knowledge of urology
  2. Demonstrate an increased knowledge base of urology
  3. Apply the increased knowledge to improve quality of patient care
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
01/01/2017
Course expires: 
01/31/2020

Disclosures

(Individuals in control of the content. All individuals with their respective disclosures listed in this document are planners. Individual authors’ disclosures are located with their articles in each issue of The Journal of Urology®.)

Planner Disclosures

Victor Nitti, MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial

Brant Inman, MD, MS: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech, Inc.: Scientific Study or Trial; Combat Medical: Consultant or Advisor; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor

The Journal of Urology® Editorial Board

NameCompanyRole
Anthony Atala MDPlureon IncLeadership Position
Daniel Ari Barocas MDNothing to disclose 
Peter Colin Black, MDGenomeDx Biosciences IncConsultant or Advisor, Scientific Study or Trial
 JanssenConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
 AstellasConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
 AmgenConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
 SitkaConsultant or Advisor
 FerringConsultant or Advisor, Meeting Participant or Lecturer
 New B InnovationScientific Study or Trial
 BiosyentConsultant or Advisor
 LillyConsultant or Advisor
 SanofiConsultant or Advisor
 SpectrumConsultant or Advisor
 Bladder CancerHealth Publishing
 PLOS ONEHealth Publishing
 BMC UrologyHealth Publishing
 MerckConsultant or Advisor
 iProgenScientific Study or Trial
 BayerConsultant or Advisor
 AbbVieConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
 RedLeaf MedicalMeeting Participant or Lecturer
 BiocancellConsultant or Advisor
 Roche/GenentechConsultant or Advisor, Scientific Study or Trial
 World Journal of UrologyHealth Publishing
 Urologic OncologyHealth Publishing
Robert Edward Brannigan MDThe American Society for Reproductive Medicine (ASRM)Leadership Position, Health Publishing
 The American Society for Reproductive MedicineLeadership Position
 AbbVie, Inc.Other
 The National Institutes of HealthOther
Mark Patrick Cain MDNothing to disclose 
Toby C. Chai MDIon Channel, Inc.Consultant or Advisor
 AllerganConsultant or Advisor, Scientific Study or Trial
Peter Earl Clark, MDGalil MedicalConsultant or Advisor
 GenentechConsultant or Advisor
Craig Vance Comiter ,MDcoloplastConsultant or Advisor
 axonicsScientific Study or Trial
 zenflowScientific Study or Trial
 Avails medicalConsultant or Advisor
 NeusperaConsultant or Advisor
Tracy M. Downs ,MDPhotocureMeeting Participant or Lecturer
Scott E. Eggener ,MDJanssen PharmaceuticalsConsultant or Advisor, Meeting Participant or Lecturer
 Myriad GeneticsConsultant or Advisor, Scientific Study or Trial
 NxTheraConsultant or Advisor
 Profound MedicalConsultant or Advisor
 Genomic HealthConsultant or Advisor, Scientific Study or Trial
 MDx HealthConsultant or Advisor, Meeting Participant or Lecturer
Brian Howard Eisner, MDRavine GroupOwner, Product Development
 Gyrus/ACMI/OlympusConsultant or Advisor
 Boston ScientificConsultant or Advisor
 BardConsultant or Advisor
 RetrophinConsultant or Advisor
 AllenaConsultant or Advisor
 Kalera MedicalConsultant or Advisor
Howard B. Goldman, MDallerganConsultant or Advisor
 astellasConsultant or Advisor
 MedtronicConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
 CookScientific Study or Trial
E. Ann Gormley MDSUFU FoundationLeadership Position
 ACGMELeadership Position
Wayne John G. Hellstrom, MDEndoConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
 TheralogixLeadership Position
 ColoplastConsultant or Advisor, Meeting Participant or Lecturer
 LillyConsultant or Advisor, Meeting Participant or Lecturer
 American Medical SystemsConsultant or Advisor
 NIHLeadership Position
 Lipocine, IncConsultant or Advisor
 New England Research Institutes, IncOther
 AbbvieConsultant or Advisor
 PfizerConsultant or Advisor
 AstellasConsultant or Advisor
 Repros TherapueticsConsultant or Advisor
 AllerganConsultant or Advisor
Ashish M. Kamat, MDFKDScientific Study or Trial
 PhotocureConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
 SanofiConsultant or Advisor, Meeting Participant or Lecturer
 Abbott MolecularConsultant or Advisor
 TheralaseConsultant or Advisor
 Telesta Therapeutics Inc. (formerly Bioniche)Consultant or Advisor
 Heat BiologicsConsultant or Advisor, Scientific Study or Trial
 Pacific Edge, LtdMeeting Participant or Lecturer
 MerckConsultant or Advisor, Scientific Study or Trial
 Spectrum PharmaceuticalsConsultant or Advisor
 OncogenixConsultant or Advisor
 CepheidConsultant or Advisor
Laurence H. Klotz, MDFerringConsultant or Advisor, Scientific Study or Trial
 AmgenConsultant or Advisor, Scientific Study or Trial
 AstellasMeeting Participant or Lecturer, Scientific Study or Trial
 MedivationMeeting Participant or Lecturer, Scientific Study or Trial
 AbbvieMeeting Participant or Lecturer, Scientific Study or Trial
 JanssenMeeting Participant or Lecturer, Scientific Study or Trial
 Profound MedicalConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Badrinath R. Konety, MDAxogen Inc.Consultant or Advisor
 Photocure IncScientific Study or Trial
 Genomic HealthScientific Study or Trial
 SpectrumScientific Study or Trial
Jaime Landman, MDCook UrologicalConsultant or Advisor, Owner, Product Development
 Galil MedicalConsultant or Advisor
 CONMEDConsultant or Advisor
 AurisConsultant or Advisor, Investment Interest
 AllerganScientific Study or Trial
Gary Evan Lemack ,MDAstellasConsultant or Advisor, Meeting Participant or Lecturer
 AllerganConsultant or Advisor, Meeting Participant or Lecturer
 SophirisScientific Study or Trial
 MedtronicConsultant or Advisor
Yair Lotan ,MDabbottScientific Study or Trial
 DanoneConsultant or Advisor, Scientific Study or Trial
 CepheidScientific Study or Trial
 Pacific EdgeScientific Study or Trial
 FKDScientific Study or Trial
 MDxHealthConsultant or Advisor
 biocancellScientific Study or Trial
 Genomic HealthScientific Study or Trial
 GenomeDx Biosciences IncScientific Study or Trial
 photocureScientific Study or Trial
William Thomas Lowrance, MDMyriad GeneticsScientific Study or Trial
 Genome DxScientific Study or Trial
 ArgosScientific Study or Trial
 Myriad GeneticsConsultant or Advisor
 Stream DxInvestment Interest
Kevin Thomas McVary ,MD, FACSAstellasScientific Study or Trial
 Lilly/ICOSConsultant or Advisor, Scientific Study or Trial, Other
 NIDDKScientific Study or Trial
 AMSConsultant or Advisor, Scientific Study or Trial
 SophrisScientific Study or Trial
Maxwell V. Meng ,MDAUAHealth Publishing
 Urologic Oncology (Journal)Health Publishing
David Christopher Miller ,MDBlue Cross Blue Shield of MichiganOther
Nicole Lara Miller ,MDLumenisMeeting Participant or Lecturer
 Boston Scientific CorporationConsultant or Advisor, Meeting Participant or Lecturer
Ajay Nehra, MDInternational Society of Mens HealthLeadership Position
 American Society of Mens HealthLeadership Position
 AUA NEWSLeadership Position
 Journal of Mens HealthLeadership Position
 Sexual Medicine Society of North AmericaLeadership Position
 ICUDMeeting Participant or Lecturer
 ICUDMeeting Participant or Lecturer
 Journal of UrologyHealth Publishing
Joel Byron Nelson MDNothing to disclose 
Mike Minh Nguyen MD,MPHNothing to disclose 
John Luther Phillips, MDNothing to disclose 
Mrs.. Deborah F. PollyNothing to disclose 
Jay D. Raman, MDAmerican Kidney Stone ManagementInvestment Interest
Bradley Fields Schwartz ,MDCook MedicalMeeting Participant or Lecturer
Ojas Shah, MDBoston ScientificConsultant or Advisor, Meeting Participant or Lecturer
 ElsevierHealth Publishing
 American Urological AssociationMeeting Participant or Lecturer, Other
 Bristol Myers SquibbInvestment Interest
 RetrophinConsultant or Advisor
 NJ Kidney Stone CenterInvestment Interest
 Glaxo Smith KlineInvestment Interest
 NovartisInvestment Interest
Joseph A. Smith Jr.,MDNothing to disclose 
Kevan A. Sternberg ,MDThe Journal of UrologyLeadership Position
Ramakrishna Venkatesh MDNothing to disclose 
Julian Hsin-Cheng Wan MDAllerganScientific Study or Trial

Accreditation

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Target Audience

The Journal of Urology® Home Study Course is designed for practicing urologic physicians, American Board of Urology (ABU) candidates and/or residents.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/ or Education Content Review Committee or its subgroup
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point- counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Evidence-based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Off label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Release Date: January, 2017.

Expiration Date: January, 2020.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.